

**BARKAT**

PHARMACEUTICAL GROUP

2020-2021

[www.bpharmed.com](http://www.bpharmed.com)



# Contents

**BARKAT AT A GLANCE**

**SUBSIDIARIES**

**ONGOING PROJECTS**

**COLLABORATION OPPORTUNITIES**



## Practical translation of self-confidence





**Dr. Akbar Borandegi**  
**CEO**

At **Barkat Pharmaceutical Group**, We develop and manufacture medicines and supplements for conditions ranging from the common cold to cancer. We possess a broad portfolio from **API to finished products and advance therapy**.

Barkat Pharmaceutical Group employs approximately **3600** people. We are proud to say that our employees are the reason for our sustained success. Their skills and dedication make us an industry leader. Their diverse perspectives, qualifications, and talents are key to our ongoing accomplishments. We believe in empowering our employees, presenting them with new challenges and letting them grow and develop professionally. We provide our people with a wide variety of jobs and fields of expertise, unique organizational culture and create opportunities for personal, professional and organizational development. At Barkat Pharmaceutical Group, We have a sense of individual and collective accountability to the importance of our mission and work together to deliver value to our patients and to our shareholders while upholding a commitment to uncompromising ethics and integrity.



# Barkat Pharmaceutical Group At a Glance

- ✚ One of the largest pharmaceutical holding companies in Iran
- ✚ The second-largest medicine importer company in Iran (by volume)
- ✚ One of the biggest distributors of Pharmaceutical and FMCG products in Iran
- ✚ One of the main manufacturer producer of Cardiovascular, CNS, Oncology & Antibiotics
- ✚ Alborz is the first investment company listed on Tehran Stock Exchange (TSE)



# Barkat Pharmaceutical Group At a Glance



Capital Investment:  
**140,000,000 \$**

Number of  
Employees :  
**3600**


More than **12%** of  
market (volume)



Export



More than 60 products of our companies have been registered in different countries:  
**Iraq, Syria, Lebanon, Afghanistan, Kazakhstan, Tajikistan, Philippines, Uganda**




Also, our companies are registered in **Iraq, Afghanistan, Syria, Uganda, Vietnam, Philippines**

[www.bpharmed.com](http://www.bpharmed.com)




# Half a Century Of Experience





# Value Chain

Family of 17 companies...





# Production Lines and Capacities

## Solids



6.2 Billion  
Tablets



730 Million  
Capsule



12 Million  
Sachet

## Injectable



72 Million  
Ampules



9 Million  
Prefilled  
Syringe



925000  
Vial

## Liquids



46.5 Million  
Syrups &  
Suspensions



6.6 Million  
Drop



1.7 Million  
Spray

## Semi-Solids



26.5 Million  
Cream and  
ointment




17 Million  
Suppository

## API




900 Tons





## Products by Therapeutics area



**127** items  
**Neurological**



**109** items  
**GI system**



**74** items  
**Cardiovascular**



**27** items  
**Analgesic**



**34** items  
**Antibiotic**



**13** items  
**Respiratory system**



**25** items  
**supplement**



**18** items  
**Anti-allergy**



**8** items  
**ENT (Eye and nose sterile medicines)**



**11** items  
**Antitussive**



**16** items  
**anti inflammator**



**8** items  
**Herbal**



**27** items  
**Dermatology**



**8** items  
**Hormone**




**57** items  
**Oncology**





Peptides



Bio-similar



Vaccine



From 85% to 100% progress depends on the projects



Investment : 350 M \$



**Cell Therapy products**



**Alogen banks**



**Joint Venture between Barkat Pharmaceutical Group & Royan  
Royan is one of the leaders in the world in Regenerative Medicine**



**Investment 7 M \$**



**The first Advanced therapy medicinal products (ATMPs) registered in MENA**



# Herbi Pharmmed



**Improve diabetes**  
Herbinorm



**Fatty liver problem Improve fatty liver function**  
Herbiliver



**Sleep disorder**  
Herbinap



**Improve the symptoms of irritable bowel syndrome**



**Anti-reflux**  
Herbireflux



**Anti-stress**  
Herbicalm



**Anti-colitis**  
Herb colitis




## Production Lines:

- Extraction Line
- Purification Line
- Condensation Line
- Drying Line



**Investment : 35 M \$**








# Corona Virus Global Concern







## Treatment

-  Remdesivir
-  Favipiravir
-  Ventilator
-  CT-SCAN



## Prevention

-  Vaccine Development in 6 platforms
-  Sanitizers
-  Mask & mask production machine
-  Ethanol 96%





# Vaccine Platforms



## Biosun Pharmed



**DNA**



**Subunit**



**Recombinant live  
measles virus**

## Cell Tech Pharmed



**m-RNA**



**Subunit**


## Shifa Pharmed



**Inactivated**










# Vaccine process





# Animal studies for evaluating the safety and efficacy of the CovIran Barkat vaccine



	Topic	Animal model and Study	
Animal Studies	Safety assay	Abnormal toxicity test 	
		Repeated dose toxicity 	
		Pyrogenicity assay 	
	Vaccine immunogenicity analysis	Evaluation of the humoral immune response 	IgG antibody titer (ELISA)
			IgG2a/IgG1
			Virus Neutralizing Test (VNT)
		Evaluation of the cellular immune response 	Blood biochemical and hematological analysis
			Cytokines assay
			Granzyme B activity assay 
			Virus quantification in lung
SARS-CoV-2 challenge		Cytokines assay	
		Histopathology and immunohistochemistry	




# Clinical Trials- Phase 1



Clinical trials  
Phase 1  
Safety  
3 micro gram  
5 micro gram

**Section 1**  
**Safety**  
Target : 18 – 50 years old  
Volunteer's : 56  
Strat date :2020/12/29  
End date :2021/03/04

**Section 2**  
**Safety and Immunogenicity**  
Target : 51 – 75 years old  
Volunteer's : 32  
Strat date : 2021/03/15  
End date : 2021/04/09






## Clinical Trials- Phase 2



**Clinical trials**  
**Phase 2**  
**Immunogenicity**  
**5 micro gram**


**Immunogenicity**  
Target : 18 – 75 years old  
Volunteer's : 280  
Strat date : 2021/03/15  
End date : 2021/05/25





## Some of volunteers






# Clinical Trials- Phase 3



**Clinical trials**  
**Phase 3**  
**Efficacy**  
**5 micro gram**

**Efficacy**  
Target : 18 – 75 years old  
Volunteer's : 20,000  
Strat date : 2021/04/16  
End date : 2021/06/29





Thanks for your attention

VP\_INTERNATIONAL@TADBIR\_GROUP.COM  
info@bpharmed.com